Abstract
CD95L-induced apoptosis involves caspase activation and is facilitated when RNA and protein synthesis are inhibited. Here, we report that hyperthermia sensitizes malignant glioma cells to CD95L- and APO2L-induced apoptosis in the absence, but not in the presence, of inhibitors of RNA and protein synthesis. Hyperthermia does not alter CD95 expression at the cell surface and does not modulate the morphology of CD95-mediated cell death on electron microscopy. Bcl-2 gene transfer inhibits apoptosis and abrogates the sensitization mediated by hyperthermia. Hyperthermia does not overcome resistance to apoptosis conferred by the viral caspase inhibitor, crm-A, indicating the absolute requirement for the activation of crm-A-sensitive caspases, probably caspase 8, for apoptosis. CD95L-evoked DEVD-amc-cleaving caspase activity is enhanced by hyperthermia, suggesting that hyperthermia operates up-stream of caspase processing to promote apoptosis. There is no uniformly enhanced processing of three caspase 3 substrates, poly-ADP ribose polymerase (PARP), protein kinase C (PKC) δ and DNA fragmentation factor (DFF) 45. Yet, hyperthermia promotes CD95L-evoked DNA fragmentation. Interestingly, hyperthermia enhances the CD95L-evoked release of cytochrome c in the absence, but not in the presence, of CHX. In contrast, the reduction of the mitochondrial membrane potential is enhanced by hyperthermia both in the absence and presence of CHX, and enhanced cytochrome c release is not associated with significantly enhanced caspase 9 processing. The potentiation of cytochrome c release at hyperthermic conditions in the absence of CHX is abrogated by Bcl-2. Thus, either hyperthermia or inhibition of protein synthesis by CHX potentiate cytotoxic cytokine-induced apoptosis. These pathways show no synergy, but rather redundance, indicating that CHX may function to promote apoptosis in response to cytotoxic cytokines by inhibiting the synthesis of specific proteins whose synthesis, function or degradation is temperature-sensitive.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bossy-Wetzel E, Newmeyer D and Green D . 1998 EMBO J 17: 37–49
Green D and Reed J . 1998 Science 281: 1309–1312
Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, Elia A, de la Pompa JL, Kagi D, Khoo W, Potter J, Yoshida R, Kaufman SA, Lowe SW, Penninger JM and Mak TW . 1998 Cell 94: 339–352
Hu Y, Benedict M, Wu D, Inohara N and Núnez G . 1998 Proc Natl Acad Sci USA 95: 4386–4391
Jiang Y, Woronicz JD, Liu W and Goeddel DV . 1999 Science 283: 543–546
Kameshita I, Mitsuuchi Y, Matsuda M and Shizuta Y . 1989 Jacobson MK and Jacobson E eds New York Springer-Verlag pp71–75
Kharbanda S, Pandey P, Schofield L, Israels S, Roncinske R, Yoshida K, Bharti A, Yuan Z-M, Saxena S, Weichselbaum R, Nalin C and Kufe D . 1997 Proc Natl Acad Sci USA 94: 6939–6942
Klostergaard J, Leroux E, Siddik Z, Khodadadian M and Tomasovic S . 1992 Cancer Res 52: 5271–5277
Kluck R, Bossy-Wetzel E, Green D and Newmeyer D . 1997 Science 275: 1132–1136
Krammer P . 1999 Adv Immunol 71: 163–210
Kroemer G . 1997 Cell Death Differ 4: 443–456
Kuida K, Haydar T, Kuan C-Y, Gu Y, Taya C, Karasuyama H, Su M-S, Rakic P and Flavell R . 1998 Cell 94: 325–337
Li F, Srinivasan A, Wang Y, Armstrong R, Tomaselli K and Fritz L . 1997 J Biol Chem 272: 30299–30305
Li H, Zhu H, Xu C and Yuan J . 1998 Cell 21: 491–501
Liu X, Zou H, Slaughter C and Wang X . 1997 Cell 89: 175–184
Luo X, Budihardjo I, Zou H, Slaughter C and Wang X . 1998 Cell 94: 481–490
Mignotte B and Vayssiere J-L . 1998 Eur J Biochem 252: 1–15
Naumann U and Weller M . 1998 Int J Cancer 77: 645–648
Pastorino J, Chen S-T, Tafani M, Snyder J and Farber J . 1998 J Biol Chem 273: 7770–7775
Pohl U, Wagenknecht B, Naumann U and Weller M . 1999 Cell Physiol Biochem 9: 29–37
Rieger J, Naumann U, Glaser T, Ashkenazi A and Weller M . 1998 FEBS Lett 427: 124–128
Roth W, Fontana A, Trepel M, Reed J, Dichgans J and Weller M . 1997 Cancer Immunol Immunother 44: 55–63
Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S and Peter M . 1998 Eur J Biochem 254: 439–459
Slee E, Harte M, Kluck R, Wolf B, Casiano C, Newmeyer D, Wang H, Reed J, Nicholson D, Alnemri E, Green D and Martin S . 1999 J Cell Biol 144: 281–292
Sminia P, van der Zee J, Wondergem J and Haveman J . 1994 Int J Hyperthermia 10: 1–30
Srinivasan A, Li F, Wong A, Kodandapani L, Smidt R, Krebs J, Fritz L, Wu J and Tomaselli K . 1998 J Biol Chem 273: 4523–4529
Stennicke HR, Deveraux QL, Humke EW, Reed JC, Dixit VM and Salvesen GS . 1999 J Biol Chem 274: 8359–8362
Takayama S, Xie Z and Reed JC . 1999 J Biol Chem 274: 781–786
Vander-Heiden M, Chandel N, Williamson E, Schumacker P and Thompson C . 1997 Cell 91: 627–637
Wagenknecht B, Schulz J, Gulbins E and Weller M . 1998 Cell Death Differ 5: 894–900
Wagenknecht B, Glaser T, Naumann U, Kügler S, Isenmann S, Bähr M, Korneluk R, Liston P and Weller M . 1999 Cell Death Differ 6: 370–376
Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M and Urushizaki I . 1988 Cancer Res 48: 650–653
Weller M, Frei K, Groscurth P, Krammer P, Yonekawa Y and Fontana A . 1994 J Clin Invest 94: 954–964
Weller M, Malipiero U, Aguzzi A, Reed J and Fontana A . 1995 J Clin Invest 95: 2633–2643
Weller M, Kleihues P, Dichgans J and Ohgaki H . 1998 Brain Pathol 8: 285–293
Wick W, Furnari F, Naumann U, Cavenee W and Weller M . 1999 Oncogene 18: 3936–3943
Yang J, Liu X, Bhalla K, Kim C, Ibrado A, Cai J, Peng T, Jones D and Wang X . 1997 Science 275: 1129–1132
Yount G, Haas-Kogan D, Levine K, Aldape K and Israel M . 1998 Cancer Res 58: 3819–3825
Acknowledgements
Supported by grants from the Fortüne program of the University of Tübingen Medical School (M Hermisson), Deutsche Forschungsgemeinschaft (We 1502/3-2) and the IZKF Tübingen to M Weller. We would like to thank Eva-Maria Knittel for skilful technical assistance in electron microscopy.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hermisson, M., Wagenknecht, B., Wolburg, H. et al. Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release. Oncogene 19, 2338–2345 (2000). https://doi.org/10.1038/sj.onc.1203554
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203554
Keywords
This article is cited by
-
Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion
Cell Death & Disease (2015)
-
Behandlung von Hirntumorpatienten
Der Nervenarzt (2012)
-
Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
Journal of Neuro-Oncology (2010)
-
Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death
Cell Death & Differentiation (2003)
-
NF-κB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells
Cell Death & Differentiation (2003)